ArticleJournal of the National Cancer Institute2024
Physical activity and checkpoint inhibition: association with toxicity and survival.
Article in Journal of the National Cancer Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.Journal for immunotherapy of cancer · 2026Guideline
- Real-world feasibility and effectiveness of a personalized exercise program during cancer treatment: results from the CHOiCE prospective study.The oncologist · 2026Trial
- Exercise therapy in cancer prevention and treatment.Nature reviews. Clinical oncology · 2026Review
- Physical activity is associated with improved survival in skin cancer patients: A meta-analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Review
- Review
- Physical activity in cancer patients receiving immune-checkpoint inhibitors: opportunities and challenges.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Exercise and antitumor immunity: molecular signaling, immune dynamics, and remodeling of the tumor microenvironment.Frontiers in immunology · 2026Review
- The impact of obesity-related systemic inflammation on the efficacy, toxicity, and biomarkers of immune checkpoint inhibitors in lung cancer: from mechanisms to clinical management.Frontiers in immunology · 2026Review
- Non-pharmacological Supportive Care Interventions during Immunotherapy for People with Cancer: A Systematic Scoping Review and Future Directions.Current oncology reports · 2025Article
- Current status of management of immune-related adverse events and practical needs for oncologist education.Cancer biology & medicine · 2025Review
- Objective measurement of physical activity levels and patient-reported outcomes in cancer patients receiving immune-checkpoint inhibitors: a cross-sectional study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Mitigation strategies for gastrointestinal (GI) immune-related adverse events for patients with solid tumors receiving immunotherapy.Immunotherapy · 2025Review
- Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study.Journal of the National Cancer Institute · 2025Article
- Association between exercise and clinical outcomes in patients treated with immunotherapy for solid tumors.Frontiers in immunology · 2025Article
- Exercise induced immune regulation and drug efficacy in rhinitis nasopharyngeal carcinoma implications for tumor microenvironment single cell immune signal transduction.Frontiers in immunology · 2025Review
- A cross-sectional study exploring the perception of exercise oncology in the Italian population.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough animal experiments suggest beneficial effects of physical activity (PA) on antitumor immunity, little is known about the effects of PA on immune checkpoint inhibitor (ICI) toxicity and effectiveness in humans. We assessed the association of PA with immune-related adverse events (irAE) and survival in patients undergoing ICI.
methodsPatients receiving ICI who completed the Dutch short questionnaire to assess health enhancing physical activity (SQUASH) questionnaire at the start of treatment as part of the prospective UNICIT study in an academic hospital were included. PA was quantified by calculating total metabolic equivalent task hours per week (total PA) and hours per week of moderate- to vigorous-intensity PA during sport and leisure time (MVPA-SL). Associations of PA with severe irAE occurrence within 1 year and overall survival (OS) were evaluated using logistic regression and Cox proportional hazard regression, respectively, with adjustment for probable confounders.
resultsIn total, 251 patients were included, with a median follow-up of 20 months. Moderate and high levels of total PA were associated with lower odds of severe irAE occurrence compared to low levels of total PA (adjusted OR: 0.34 [95% CI = 0.12 to 0.90] and 0.19 [95% CI = 0.05 to 0.55], respectively). Moderate and high levels of total PA were also associated with prolonged survival (adjusted HR: 0.58 [95% CI = 0.32 to 1.04] and 0.48 [95% CI = 0.27 to 0.89], respectively). Similar associations were observed in patients who performed more MVPA-SL.
conclusionsHigher physical activity levels at the start of ICI treatment are associated with lower risk of severe irAEs and probably prolonged survival. Randomized controlled trials are needed to investigate whether patients indeed benefit from increasing PA levels after diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.